ImmunityBio Enhances Advertising Compliance Measures
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy IBRX?
Source: Newsfilter
- Advertising Compliance Review: ImmunityBio has conducted a comprehensive review of all promotional materials and implemented enhanced advertising compliance measures, including expanded review protocols and executive training, thereby ensuring future communications align with FDA regulations and mitigating potential legal risks.
- Podcast Removal Action: The company has removed the identified podcast from its corporate website and formally requested its deletion from third-party platforms, aiming to eliminate public misunderstandings regarding its promotional content and maintain brand integrity.
- Television Advertisement Clarification: ImmunityBio confirmed that the television advertisement mentioned in the FDA correspondence was never aired, which not only underscores the company's commitment to compliance but also demonstrates its dedication to transparency, potentially boosting investor confidence.
- Scientific Innovation Context: In its response, the company provided background on the IL-15 molecule, emphasizing its potential in cancer treatment, which not only helps clarify public understanding of its R&D direction but may also attract more investor interest in its innovative capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.860
Low
5.00
Averages
7.33
High
9.00
Current: 6.860
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IBRX Stock Poised to End Two-Day Decline as Anktiva Gains Attention Before COVID-Cancer Link Data Release
COVID-19 and Cancer Link: Upcoming data will highlight a connection between COVID-related immune cell loss and the spread of breast cancer, to be presented at a cancer summit next week.
Funding and Market Expansion: Immunity Bio has secured $100 million in financing to support its European rollout plans under an "immunotherapy 2.0" strategy, expanding its reach across 33 countries.
Stock Performance: Shares of Immunity Bio (IBRX) rose by 6% in premarket trading following positive announcements regarding upcoming cancer data and the company's European campaign launch.
Clinical Observations: Clinicians are reporting increased incidences of metastatic disease and cancer recurrence in patients post-COVID infection, validating concerns about immune imbalances exacerbated by the virus.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting serious concerns about the company's promotional practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its advertising and podcast content were misleading, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to come forward, indicating potential legal risks that could affect the company's future financing and market reputation.
- Public Health Implications: The FDA emphasized that ImmunityBio's promotional materials grossly misrepresent the benefits of Anktiva, potentially misleading patients about treatment expectations, which raises compliance issues and could lead to stricter regulatory scrutiny.
See More
ImmunityBio Faces Class Action Lawsuit Over Misleading Claims
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased ImmunityBio (NASDAQ:IBRX) securities between January 19 and March 24, 2026, can seek lead plaintiff status by May 26, 2026, highlighting investor concerns over potential fraudulent activities by the company.
- False Statement Allegations: The lawsuit alleges that ImmunityBio and its Executive Chairman made false and misleading statements during the class period, claiming that their lead biologic product Anktiva could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated, potentially leading to significant investor losses.
- FDA Warning Impact: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock indicated that promotional materials for Anktiva were misleading and violated the Federal Food, Drug, and Cosmetic Act, resulting in a 21% drop in ImmunityBio's stock price, reflecting market concerns about the company's compliance.
- Law Firm Background: Robbins Geller is one of the world's leading law firms in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, demonstrating its strong capabilities and influence in the securities class action landscape.
See More
ImmunityBio Investors File Class Action Lawsuit Over FDA Warning
- Class Action Notice: Investors in ImmunityBio, Inc. are reminded that those who purchased the company's securities between January 19, 2026, and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit against the company.
- FDA Warning Impact: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock highlighted misleading advertising claims regarding Anktiva, which violated the Federal Food, Drug, and Cosmetic Act, directly affecting investor confidence and raising concerns about the company's compliance.
- Significant Stock Drop: Following the FDA warning, ImmunityBio's stock price plummeted by 21%, losing $1.98 per share to close at $7.42, reflecting market apprehension regarding the company's regulatory compliance and future outlook.
- Legal Consequences: The lawsuit alleges that ImmunityBio and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to substantial legal and financial risks.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio, Inc. (IBRX) is facing a class action lawsuit for securities fraud, alleging significant misstatements and omissions regarding its lead biologic product, Anktiva, during the period from January 19 to March 24, 2026, which may have resulted in investor losses.
- Stock Price Plunge: Following an FDA warning on March 24, 2026, regarding false claims about Anktiva, ImmunityBio's stock price fell by $1.98, or 21.12%, closing at $7.42 per share, indicating severe market concerns about the company's future prospects.
- Investor Action: Affected investors are encouraged to apply for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, with Kessler Topaz Meltzer & Check, LLP offering free consultations and emphasizing no cost obligations.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud class actions, having recovered over $25 billion for clients and represented major institutional investors, showcasing its significant influence and expertise in securities litigation.
See More
ImmunityBio Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without additional financial burden.
- Case Background: The lawsuit alleges that ImmunityBio made false or misleading statements during the class period, resulting in investor losses when the truth emerged, highlighting significant implications for the company's operations and prospects.
- Law Firm Credentials: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
IBRX Stock Poised to End Two-Day Decline as Anktiva Gains Attention Before COVID-Cancer Link Data Release
COVID-19 and Cancer Link: Upcoming data will highlight a connection between COVID-related immune cell loss and the spread of breast cancer, to be presented at a cancer summit next week.
Funding and Market Expansion: Immunity Bio has secured $100 million in financing to support its European rollout plans under an "immunotherapy 2.0" strategy, expanding its reach across 33 countries.
Stock Performance: Shares of Immunity Bio (IBRX) rose by 6% in premarket trading following positive announcements regarding upcoming cancer data and the company's European campaign launch.
Clinical Observations: Clinicians are reporting increased incidences of metastatic disease and cancer recurrence in patients post-COVID infection, validating concerns about immune imbalances exacerbated by the virus.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting serious concerns about the company's promotional practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its advertising and podcast content were misleading, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to come forward, indicating potential legal risks that could affect the company's future financing and market reputation.
- Public Health Implications: The FDA emphasized that ImmunityBio's promotional materials grossly misrepresent the benefits of Anktiva, potentially misleading patients about treatment expectations, which raises compliance issues and could lead to stricter regulatory scrutiny.
See More
ImmunityBio Faces Class Action Lawsuit Over Misleading Claims
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased ImmunityBio (NASDAQ:IBRX) securities between January 19 and March 24, 2026, can seek lead plaintiff status by May 26, 2026, highlighting investor concerns over potential fraudulent activities by the company.
- False Statement Allegations: The lawsuit alleges that ImmunityBio and its Executive Chairman made false and misleading statements during the class period, claiming that their lead biologic product Anktiva could make all NMIBC patients cancer-free long-term, a claim that has not been substantiated, potentially leading to significant investor losses.
- FDA Warning Impact: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock indicated that promotional materials for Anktiva were misleading and violated the Federal Food, Drug, and Cosmetic Act, resulting in a 21% drop in ImmunityBio's stock price, reflecting market concerns about the company's compliance.
- Law Firm Background: Robbins Geller is one of the world's leading law firms in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, demonstrating its strong capabilities and influence in the securities class action landscape.
See More
ImmunityBio Investors File Class Action Lawsuit Over FDA Warning
- Class Action Notice: Investors in ImmunityBio, Inc. are reminded that those who purchased the company's securities between January 19, 2026, and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit against the company.
- FDA Warning Impact: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock highlighted misleading advertising claims regarding Anktiva, which violated the Federal Food, Drug, and Cosmetic Act, directly affecting investor confidence and raising concerns about the company's compliance.
- Significant Stock Drop: Following the FDA warning, ImmunityBio's stock price plummeted by 21%, losing $1.98 per share to close at $7.42, reflecting market apprehension regarding the company's regulatory compliance and future outlook.
- Legal Consequences: The lawsuit alleges that ImmunityBio and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to substantial legal and financial risks.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio, Inc. (IBRX) is facing a class action lawsuit for securities fraud, alleging significant misstatements and omissions regarding its lead biologic product, Anktiva, during the period from January 19 to March 24, 2026, which may have resulted in investor losses.
- Stock Price Plunge: Following an FDA warning on March 24, 2026, regarding false claims about Anktiva, ImmunityBio's stock price fell by $1.98, or 21.12%, closing at $7.42 per share, indicating severe market concerns about the company's future prospects.
- Investor Action: Affected investors are encouraged to apply for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, with Kessler Topaz Meltzer & Check, LLP offering free consultations and emphasizing no cost obligations.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud class actions, having recovered over $25 billion for clients and represented major institutional investors, showcasing its significant influence and expertise in securities litigation.
See More
ImmunityBio Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without additional financial burden.
- Case Background: The lawsuit alleges that ImmunityBio made false or misleading statements during the class period, resulting in investor losses when the truth emerged, highlighting significant implications for the company's operations and prospects.
- Law Firm Credentials: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
